Environmental risk assessment of human and veterinary medicinal products - Challenges and ways of improvement

István Sebestyén, K. Monostory, Gábor Hirka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Assessment of the environmental impact, the risk posed by application of medicinal products for human and veterinary use is a legal obligation, and must be performed to evaluate and limit potential adverse effects of medicines on the environment. An environmental risk assessment (ERA) is performed in a stepwise approach in European Union, which starts with an initial screening phase (Phase I), aimed at identifying the environmental exposure of pharmaceuticals based on their potential for bioaccumulation and persistence in the environment. If, following this preliminary assessment, significant environmental exposure is anticipated, or if specific risks are identified due to compound-specific characteristics, a number of studies should be performed (Phase II) based on the guidance documents issued by European Medicines Agency (EMA). The Phase II tests identify the fate of medicinal products in the environment and their potential effects on representative organisms (e.g. fish or daphnids, for the aquatic environment). For this purpose, the results of various internationally accepted test methodologies (laid down mainly by the Organisation for Economic Co-operation and Development (OECD)) form the basis of the risk-assessment process, which may be further extended on a case-by-case basis, depending on the outcome of the assessment. However, several studies have been published revealing considerable residue levels in surface waters, in rivers and lakes throughout Europe that rise the question whether the current legislation and environmental risk assessment system of human and veterinary medicinal products are sufficiently protective.

Original languageEnglish
Pages (from-to)67-70
Number of pages4
JournalMicrochemical Journal
Volume136
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Risk assessment
Medicine
Bioaccumulation
Bioelectric potentials
Surface waters
Fish
Environmental impact
Lakes
Screening
Rivers
Economics
Pharmaceutical Preparations
Environmental assessments
European Union

Keywords

  • Challenges
  • Environmental risk assessment
  • Medicinal product
  • Recommendations for improvement

ASJC Scopus subject areas

  • Analytical Chemistry
  • Spectroscopy

Cite this

Environmental risk assessment of human and veterinary medicinal products - Challenges and ways of improvement. / Sebestyén, István; Monostory, K.; Hirka, Gábor.

In: Microchemical Journal, Vol. 136, 01.01.2018, p. 67-70.

Research output: Contribution to journalArticle

@article{55bce0f8a4784ecea64aaee1d91e38ba,
title = "Environmental risk assessment of human and veterinary medicinal products - Challenges and ways of improvement",
abstract = "Assessment of the environmental impact, the risk posed by application of medicinal products for human and veterinary use is a legal obligation, and must be performed to evaluate and limit potential adverse effects of medicines on the environment. An environmental risk assessment (ERA) is performed in a stepwise approach in European Union, which starts with an initial screening phase (Phase I), aimed at identifying the environmental exposure of pharmaceuticals based on their potential for bioaccumulation and persistence in the environment. If, following this preliminary assessment, significant environmental exposure is anticipated, or if specific risks are identified due to compound-specific characteristics, a number of studies should be performed (Phase II) based on the guidance documents issued by European Medicines Agency (EMA). The Phase II tests identify the fate of medicinal products in the environment and their potential effects on representative organisms (e.g. fish or daphnids, for the aquatic environment). For this purpose, the results of various internationally accepted test methodologies (laid down mainly by the Organisation for Economic Co-operation and Development (OECD)) form the basis of the risk-assessment process, which may be further extended on a case-by-case basis, depending on the outcome of the assessment. However, several studies have been published revealing considerable residue levels in surface waters, in rivers and lakes throughout Europe that rise the question whether the current legislation and environmental risk assessment system of human and veterinary medicinal products are sufficiently protective.",
keywords = "Challenges, Environmental risk assessment, Medicinal product, Recommendations for improvement",
author = "Istv{\'a}n Sebesty{\'e}n and K. Monostory and G{\'a}bor Hirka",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.microc.2017.08.012",
language = "English",
volume = "136",
pages = "67--70",
journal = "Microchemical Journal",
issn = "0026-265X",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Environmental risk assessment of human and veterinary medicinal products - Challenges and ways of improvement

AU - Sebestyén, István

AU - Monostory, K.

AU - Hirka, Gábor

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Assessment of the environmental impact, the risk posed by application of medicinal products for human and veterinary use is a legal obligation, and must be performed to evaluate and limit potential adverse effects of medicines on the environment. An environmental risk assessment (ERA) is performed in a stepwise approach in European Union, which starts with an initial screening phase (Phase I), aimed at identifying the environmental exposure of pharmaceuticals based on their potential for bioaccumulation and persistence in the environment. If, following this preliminary assessment, significant environmental exposure is anticipated, or if specific risks are identified due to compound-specific characteristics, a number of studies should be performed (Phase II) based on the guidance documents issued by European Medicines Agency (EMA). The Phase II tests identify the fate of medicinal products in the environment and their potential effects on representative organisms (e.g. fish or daphnids, for the aquatic environment). For this purpose, the results of various internationally accepted test methodologies (laid down mainly by the Organisation for Economic Co-operation and Development (OECD)) form the basis of the risk-assessment process, which may be further extended on a case-by-case basis, depending on the outcome of the assessment. However, several studies have been published revealing considerable residue levels in surface waters, in rivers and lakes throughout Europe that rise the question whether the current legislation and environmental risk assessment system of human and veterinary medicinal products are sufficiently protective.

AB - Assessment of the environmental impact, the risk posed by application of medicinal products for human and veterinary use is a legal obligation, and must be performed to evaluate and limit potential adverse effects of medicines on the environment. An environmental risk assessment (ERA) is performed in a stepwise approach in European Union, which starts with an initial screening phase (Phase I), aimed at identifying the environmental exposure of pharmaceuticals based on their potential for bioaccumulation and persistence in the environment. If, following this preliminary assessment, significant environmental exposure is anticipated, or if specific risks are identified due to compound-specific characteristics, a number of studies should be performed (Phase II) based on the guidance documents issued by European Medicines Agency (EMA). The Phase II tests identify the fate of medicinal products in the environment and their potential effects on representative organisms (e.g. fish or daphnids, for the aquatic environment). For this purpose, the results of various internationally accepted test methodologies (laid down mainly by the Organisation for Economic Co-operation and Development (OECD)) form the basis of the risk-assessment process, which may be further extended on a case-by-case basis, depending on the outcome of the assessment. However, several studies have been published revealing considerable residue levels in surface waters, in rivers and lakes throughout Europe that rise the question whether the current legislation and environmental risk assessment system of human and veterinary medicinal products are sufficiently protective.

KW - Challenges

KW - Environmental risk assessment

KW - Medicinal product

KW - Recommendations for improvement

UR - http://www.scopus.com/inward/record.url?scp=85027715083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027715083&partnerID=8YFLogxK

U2 - 10.1016/j.microc.2017.08.012

DO - 10.1016/j.microc.2017.08.012

M3 - Article

AN - SCOPUS:85027715083

VL - 136

SP - 67

EP - 70

JO - Microchemical Journal

JF - Microchemical Journal

SN - 0026-265X

ER -